Northwestern Medicine Regional Medical GroupNorthwestern Medicine Regional Cardiology 351 Delnor Dr STE 100, Geneva, IL 60134 (630)2320280 (phone), (630)9389599 (fax)
Education:
Medical School Loyola University Chicago Stritch School of Medicine Graduated: 1989
Procedures:
Cardiac Catheterization Cardiac Stress Test Cardioversion Continuous EKG Echocardiogram Electrocardiogram (EKG or ECG) Pacemaker and Defibrillator Procedures
Dr. Severino graduated from the Loyola University Chicago Stritch School of Medicine in 1989. He works in Geneva, IL and specializes in Cardiovascular Disease. Dr. Severino is affiliated with Central Dupage Hospital and Delnor Community Hospital.
he sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Michael Severino sold 25,633 shares of AbbVie stock in a transaction that occurred on Friday, November 10th. The stock was sold at an average price of $94.69,
Date: Jan 27, 2018
Category: Business
Source: Google
AbbVie Announces Four New Global Research Collaborations Focused on Advancing Next-Generation Science
"We can develop tomorrow's most important therapies by investing in today's leading technologies and scientific achievements," said Michael Severino, M.D., executive vice president, research and development and chief scientific officer, AbbVie. "Combining the strengths of AbbVie's discovery and deve
Date: Jan 09, 2017
Category: Health
Source: Google
AbbVie (ABBV) Updates on Glecaprevir/Pibrentasvir Treatment Regiment in HCV; High SVR12 Rates Noted at 8 Weeks
"The results we announced today bring us closer to providing a potential pan-genotypic, once-daily treatment option with 8 weeks of therapy for people living without cirrhosis and who are new to treatment," said Michael Severino, M.D., executive vice president, research and development and chief sci
Date: Nov 11, 2016
Category: Health
Source: Google
Biogen & AbbVie's Injectable Approved in EU for Treatment of MS
With the approval of ZINBRYTA in the European Union, we are providing a much needed treatment option for people living with MS, said Michael Severino, M.D., executive vice president, research and development and chief scientific officer, AbbVie. This is an important part of AbbVies ongoing commi
Date: Jul 05, 2016
Category: Health
Source: Google
FDA approves AbbVie/Biogen's monthly MS jab, but with safety warnings
"MS patients are in need of therapeutic choices to help manage their disease and Zinbryta is an important new option for patients," said Michael Severino, executive vice president, research and development and chief scientific officer, AbbVie. "AbbVie is committed to making a remarkable impact on th
Date: May 28, 2016
Category: Health
Source: Google
AbbVie to Buy Cancer Drugmaker Stemcentrx for $5.8 Billion
We have a very strong and growing position in blood cancers and an expanding effort in solid tumors, Michael Severino, executive vice president of research and development, said by phone. The CytomX and Argenx deals involve earlier-stage programs, while the Stemcentrx acquisition adds a later-s
Date: Apr 28, 2016
Category: Business
Source: Google
Healthcare Pre-session Mover in Hot Glance: AbbVie Inc. (NYSE:ABBV), CytRx Corporation (NASDAQ:CYTR)
The executive vice president, research and development and chief scientific officer, AbbVie, Michael Severino stated that they are constantly striving to advance clinical care for patients living with chronic hepatitis C. This authorization is particularly important for the reason that patients with
Date: Apr 25, 2016
Category: Health
Source: Google
AbbVie (ABBV) Receives FDA Approval of Viekira Pak sNDA for Use Without RBV
"We are constantly striving to advance clinical care for patients living with chronic hepatitis C," said Michael Severino, M.D., executive vice president, research and development and chief scientific officer, AbbVie. "This approval is especially significant because patients with chronic HCV with co